Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy ParticipantsXiaoyan Zhang, Asher D. Schachter, Lee Andrews et al.|Clinical Pharmacology in Drug Development|2023Cited by 5
Subcutaneous VIS649, an APRIL-Neutralizing Antibody: Preliminary Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of VIS649-102, a Phase 1, Single Ascending Dose Study in Healthy VolunteersXiaoyan Zhang, Susan Sloan, Yanlin Wang et al.|Journal of the American Society of Nephrology|2021Cited by 0